Drugs / Autologous BMMC transplantation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03468699 | Jan 2017 → Sep 2021 | cirrhosis of liver | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous BMMC transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03468699 ↗ |
| Known as | BMMNC | “To evaluate the safety and early outcomes of autologous bone marrow mononuclear cell (BMMNC) infusion for liver cirrhosis due to biliary atresia (BA) after Kasai operation.” PMID 35287722 ↗ Mar 2022 |
| Modality | Cell therapy | “No severe adverse events associated with the cell therapy were observed in the patients.” PMID 35287722 ↗ Mar 2022 |
| Route | Other | “Mononuclear cells (MNCs) were isolated by Ficoll gradient centrifugation and then infused into the hepatic artery.” PMID 35287722 ↗ Mar 2022 |